{"title":"左旋多巴能预防帕金森病患者的认知能力下降吗?","authors":"Masahiro Ikeda, Hiroshi Kataoka, Satoshi Ueno","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Cognitive impairment in Parkinson's disease (PD) will become more important since the number of elderly patients with PD is increasing. We prospectively studied non-demented patients with PD over the course of 3 years to identify factors associated with PD that contribute to a decline in cognitive function. From among 100 consecutive patients, we registered 79 patients with PD. A total of 55 patients completed the study during 3 years and were divided to two groups: patients with a decline in cognitive function and those without a decline in cognitive function after 3 years. Seventeen independent variables were evaluated with the use of logistic regression models. The increase in the daily levodopa dose was related to a decline in cognitive function on univariate logistic regression analysis (OR = 0.279, p = 0.024, 95% CI = 0.092-0.848). Other variables were not related to a decline in cognitive function. The increase in the daily dose of levodopa was greater in patients without a decline in cognitive function than those with a decline in cognitive function; on the other hand, the cognitive function unchanged. Our results suggest that the treatment with levodopa might prevent a decline in cognitive function in PD.</p>","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":"6 2","pages":"9-14"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498848/pdf/ajnd0006-0009.pdf","citationCount":"0","resultStr":"{\"title\":\"Can levodopa prevent cognitive decline in patients with Parkinson's disease?\",\"authors\":\"Masahiro Ikeda, Hiroshi Kataoka, Satoshi Ueno\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cognitive impairment in Parkinson's disease (PD) will become more important since the number of elderly patients with PD is increasing. We prospectively studied non-demented patients with PD over the course of 3 years to identify factors associated with PD that contribute to a decline in cognitive function. From among 100 consecutive patients, we registered 79 patients with PD. A total of 55 patients completed the study during 3 years and were divided to two groups: patients with a decline in cognitive function and those without a decline in cognitive function after 3 years. Seventeen independent variables were evaluated with the use of logistic regression models. The increase in the daily levodopa dose was related to a decline in cognitive function on univariate logistic regression analysis (OR = 0.279, p = 0.024, 95% CI = 0.092-0.848). Other variables were not related to a decline in cognitive function. The increase in the daily dose of levodopa was greater in patients without a decline in cognitive function than those with a decline in cognitive function; on the other hand, the cognitive function unchanged. Our results suggest that the treatment with levodopa might prevent a decline in cognitive function in PD.</p>\",\"PeriodicalId\":72170,\"journal\":{\"name\":\"American journal of neurodegenerative disease\",\"volume\":\"6 2\",\"pages\":\"9-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498848/pdf/ajnd0006-0009.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of neurodegenerative disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of neurodegenerative disease","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
随着老年帕金森病患者数量的不断增加,帕金森病患者的认知功能障碍将变得越来越重要。我们前瞻性地研究了3年的非痴呆PD患者,以确定与PD相关的导致认知功能下降的因素。在100例连续患者中,我们登记了79例PD患者。共有55名患者在3年内完成了研究,并分为两组:认知功能下降的患者和3年后认知功能未下降的患者。使用逻辑回归模型对17个自变量进行评估。单因素logistic回归分析显示,左旋多巴日剂量增加与认知功能下降相关(OR = 0.279, p = 0.024, 95% CI = 0.092 ~ 0.848)。其他变量与认知功能的下降无关。无认知功能下降的患者左旋多巴日剂量的增加大于认知功能下降的患者;另一方面,认知功能不变。我们的研究结果表明,左旋多巴治疗可以预防帕金森病的认知功能下降。
Can levodopa prevent cognitive decline in patients with Parkinson's disease?
Cognitive impairment in Parkinson's disease (PD) will become more important since the number of elderly patients with PD is increasing. We prospectively studied non-demented patients with PD over the course of 3 years to identify factors associated with PD that contribute to a decline in cognitive function. From among 100 consecutive patients, we registered 79 patients with PD. A total of 55 patients completed the study during 3 years and were divided to two groups: patients with a decline in cognitive function and those without a decline in cognitive function after 3 years. Seventeen independent variables were evaluated with the use of logistic regression models. The increase in the daily levodopa dose was related to a decline in cognitive function on univariate logistic regression analysis (OR = 0.279, p = 0.024, 95% CI = 0.092-0.848). Other variables were not related to a decline in cognitive function. The increase in the daily dose of levodopa was greater in patients without a decline in cognitive function than those with a decline in cognitive function; on the other hand, the cognitive function unchanged. Our results suggest that the treatment with levodopa might prevent a decline in cognitive function in PD.